Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update.
Crit Care
; 28(1): 69, 2024 03 05.
Article
em En
| MEDLINE
| ID: mdl-38444031
ABSTRACT
BACKGROUND:
Chimeric antigen receptor T cells are a promising new immunotherapy for haematological malignancies. Six CAR-T cells products are currently available for adult patients with refractory or relapsed high-grade B cell malignancies, but they are associated with severe life-threatening toxicities and side effects that may require admission to ICU.OBJECTIVE:
The aim of this short pragmatic review is to synthesize for intensivists the knowledge on CAR-T cell therapy with emphasis on CAR-T cell-induced toxicities and ICU management of complications according to international recommendations, outcomes and future issues.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Hematológicas
/
Receptores de Antígenos Quiméricos
Limite:
Adult
/
Humans
Idioma:
En
Revista:
Crit Care
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
França